BRPI0606594A2 - sal de adição de ácido, método de preparação, solução aquosa, bem como uso do mesmo, processo para preparação de piperidin-4-ilamida do ácido 4-(2,6-dicloro-benzoilamino)-1h-pirazol-3-carboxìlico e uso do mesmo, composição farmacêutica e intermediário quìmico - Google Patents

sal de adição de ácido, método de preparação, solução aquosa, bem como uso do mesmo, processo para preparação de piperidin-4-ilamida do ácido 4-(2,6-dicloro-benzoilamino)-1h-pirazol-3-carboxìlico e uso do mesmo, composição farmacêutica e intermediário quìmico

Info

Publication number
BRPI0606594A2
BRPI0606594A2 BRPI0606594-5A BRPI0606594A BRPI0606594A2 BR PI0606594 A2 BRPI0606594 A2 BR PI0606594A2 BR PI0606594 A BRPI0606594 A BR PI0606594A BR PI0606594 A2 BRPI0606594 A2 BR PI0606594A2
Authority
BR
Brazil
Prior art keywords
benzoylamino
pyrazol
ylamide
dichloro
preparation
Prior art date
Application number
BRPI0606594-5A
Other languages
English (en)
Inventor
Paul Graham Wyatt
David Charles Rees
Mladen Vinkovic
Gary Trewartha
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0501475A external-priority patent/GB0501475D0/en
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of BRPI0606594A2 publication Critical patent/BRPI0606594A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)

Abstract

SAL DE ADIçãO DE áCIDO, MéTODO DE PREPARAçãO, SOLUçãO AQUOSA, BEM COMO USO DO MESMO, PROCESSO PARA PREPARAçãO DE PIPERIDIN-4-ILAMIDA DO áCIDO 4-(2,6-DICLORO-BENZOILAMINO)-1 H-PIRAZOL-3-CARBOXìLICO E USO DO MESMO, COMPOSIçãO FARMACêUTICA E INTERMEDIáRIO QUìMICO. A presente invenção refere-se a um sal de adição de ácido de piperidin-4-ilamida do ácido 4-(2,6-dicloro-benzoilamino)-1 H-pirazol-3-carbo-xílico e cristais do mesmo, o sal sendo formado com um ácido selecionado de ácido metanossulfónico e ácido acético e misturas dos mesmos. Também são fornecidos usos dos sais de piperidin-4-ilamida do ácido 4-(2 ,6-d icloro-benzoilamino)-1 H-pirazol-3-carboxíl ico, processos para a preparação de piperidin-4-ilamida do ácido 4-(2,6-dicloro-benzoilamino)-1H-pirazol-3-carboxílico e seus sais e intermediários químicos.
BRPI0606594-5A 2005-01-21 2006-01-20 sal de adição de ácido, método de preparação, solução aquosa, bem como uso do mesmo, processo para preparação de piperidin-4-ilamida do ácido 4-(2,6-dicloro-benzoilamino)-1h-pirazol-3-carboxìlico e uso do mesmo, composição farmacêutica e intermediário quìmico BRPI0606594A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64597305P 2005-01-21 2005-01-21
GB0501475A GB0501475D0 (en) 2005-01-22 2005-01-22 Pharmaceutical compounds
PCT/GB2006/000207 WO2006077426A2 (en) 2005-01-21 2006-01-20 4- (2, 6-DICHLOROBENZOYLAMINO) -lH-PYRAZOLE-3 -CARBOXYLIC ACID PIPERIDIN- 4 -YLAMID ACID ADDITION SALTS AS KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
BRPI0606594A2 true BRPI0606594A2 (pt) 2009-07-07

Family

ID=36129898

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606594-5A BRPI0606594A2 (pt) 2005-01-21 2006-01-20 sal de adição de ácido, método de preparação, solução aquosa, bem como uso do mesmo, processo para preparação de piperidin-4-ilamida do ácido 4-(2,6-dicloro-benzoilamino)-1h-pirazol-3-carboxìlico e uso do mesmo, composição farmacêutica e intermediário quìmico

Country Status (18)

Country Link
US (2) US8013163B2 (pt)
EP (1) EP1846393B1 (pt)
JP (1) JP5184892B2 (pt)
KR (1) KR101344691B1 (pt)
AR (1) AR054425A1 (pt)
AU (1) AU2006207323B2 (pt)
BR (1) BRPI0606594A2 (pt)
CA (1) CA2593560C (pt)
IL (1) IL184504A (pt)
MA (1) MA29256B1 (pt)
MX (1) MX2007008783A (pt)
NO (1) NO340738B1 (pt)
NZ (1) NZ556471A (pt)
PE (2) PE20061018A1 (pt)
RU (1) RU2410385C2 (pt)
SA (1) SA06260465B1 (pt)
TN (1) TNSN07277A1 (pt)
WO (1) WO2006077426A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2532965C (en) * 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
AU2006207321B2 (en) * 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
US8404718B2 (en) * 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
CN101146533A (zh) * 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 吡唑激酶抑制剂和其它抗肿瘤剂的组合
WO2006077428A1 (en) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
AR052660A1 (es) * 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
JP5138220B2 (ja) * 2005-03-03 2013-02-06 三菱レイヨン株式会社 ポリマー粒子を含む樹脂組成物、成形体
JP2008538750A (ja) 2005-04-13 2008-11-06 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2027109A1 (en) * 2006-05-05 2009-02-25 Astex Therapeutics Limited 4- (2, 6-dichloro-benzoylamino) -1h-pyrazole-s-carboxylic acid (1-methanesulph0nyl-piperidin-4-yl) -amide for the treatment of cancer
EP2026805A1 (en) * 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
EP2049516A2 (en) * 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical compounds
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044054A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in therapy
US8916552B2 (en) * 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US8399418B2 (en) 2007-12-27 2013-03-19 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
CN108713019B (zh) 2016-03-17 2021-06-15 豪夫迈·罗氏有限公司 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
KR102466192B1 (ko) 2016-08-23 2022-11-14 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포성 암종의 치료를 위한 조합 요법
EP4218820A3 (en) 2017-03-16 2023-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917432A (en) 1954-10-05 1959-12-15 Burroughs Wellcome Co Leukemia treatment
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
GB1354939A (en) 1971-10-28 1974-06-05 Ici Ltd Process for the manufacture of 1,1,2-triphenylalk-1-enes
US4005063A (en) 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4282361A (en) 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
DE2845574A1 (de) 1978-10-19 1980-04-24 Deutsches Krebsforsch Durch heterocyclische ringe oder alkylreste substituierte analoga von ccnu und verfahren zu deren herstellung
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
JPS6425763A (en) 1987-04-24 1989-01-27 Mitsubishi Chem Ind Pyrazoles and insecticide and acaricide containing said pyrazoles as active ingredient
US5164196A (en) 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5002755A (en) 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
EP0531369A1 (de) 1990-05-26 1993-03-17 Byk Gulden Lomberg Chemische Fabrik Gmbh 1,4-dihydropyridine zur anwendung bei der überwindung von arzneimittelresistenzen
IL100110A0 (en) 1990-12-26 1992-08-18 American Cyanamid Co Insecticidal and synergistic miticidal compositions
CA2119155C (en) 1991-10-18 1999-06-15 Dennis Paul Phillion Fungicides for the control of take-all disease of plants
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JP2862374B2 (ja) 1992-12-17 1999-03-03 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニスト活性を有するピラゾール及びピラゾロピリミジン
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ES2219670T3 (es) 1994-11-10 2004-12-01 Millennium Pharmaceuticals, Inc. Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis.
US5502068A (en) 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036585A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036881A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507592A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
EP0910571B1 (en) 1996-05-03 2005-07-20 Abbott Laboratories Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
AU724541B2 (en) 1996-06-21 2000-09-21 Allergan, Inc. Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
CA2275796A1 (en) 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Nitrogen containing heteroaromatics as factor xa inhibitors
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CN1281588C (zh) 1997-04-25 2006-10-25 美国辉瑞有限公司 制备吡唑并嘧啶酮类化合物的新型中间体
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
ES2239806T3 (es) 1997-06-19 2005-10-01 Bristol-Myers Squibb Pharma Company Inhibidores del factor xa con un grupo de especificidad neutro p1.
EP1040108B1 (en) 1997-12-19 2004-02-25 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
IL136637A0 (en) 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
WO1999067235A1 (fr) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Co., Ltd. Composes cycliques a cinq elements
JP2000186092A (ja) 1998-12-22 2000-07-04 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１の製造法
CA2320730A1 (en) 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
DE60003025T2 (de) 1999-04-02 2004-03-18 Bristol-Myers Squibb Pharma Co. Arylsulfonyle als faktor xa inhibitoren
BR0009721A (pt) 1999-04-15 2002-02-13 Bristol Myers Squibb Co Inibidores de tirosina quinase de proteìna cìclica
US6166244A (en) 1999-05-07 2000-12-26 Allergan Sales, Inc. Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity
WO2000071515A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc INHIBITORS OF FACTOR Xa
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
AU6936500A (en) 1999-08-24 2001-03-19 Regents Of The University Of California, The Non-quinoline inhibitors of malaria parasites
MX228790B (es) 1999-09-17 2005-06-30 Millennium Pharm Inc Inhibidores del factor xa.
ATE412629T1 (de) 1999-09-17 2008-11-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren von faktor xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6485907B1 (en) 2000-01-11 2002-11-26 Syngenta Participations Ag PCR-based detection of Rhizoctonia cerealis
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
US20040087798A1 (en) 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
WO2001081345A1 (fr) 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Composes d'amides aromatiques
MXPA02010608A (es) 2000-04-27 2003-05-14 Abbott Lab Inhibidores de farnesiltransferasa sustituidos con fenilo.
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
MXPA03000923A (es) 2000-07-31 2003-06-09 Smithkline Beecham Plc Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano.
MXPA03001785A (es) 2000-08-31 2003-06-04 Pfizer Prod Inc Derivados de pirazol y su uso como inhibidores de proteina cinasa.
WO2002022603A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1414804A1 (en) 2000-10-20 2004-05-06 Bristol-Myers Squibb Pharma Company Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors
US6455559B1 (en) 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
CN1486310A (zh) 2000-12-21 2004-03-31 ��̩��˹ҩ��ɷ����޹�˾ 可用作蛋白激酶抑制剂的吡唑化合物
DE10064823A1 (de) 2000-12-22 2002-06-27 Knoll Ag Integrinrezeptorliganden
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US20050260277A1 (en) 2001-02-28 2005-11-24 Giles Brian C Method and formula for anti-tumor and anti-matastatic effect
WO2002070483A1 (en) 2001-03-05 2002-09-12 E. I. Du Pont De Nemours And Company Heterocyclic diamide invertebrate pest control agents
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
WO2002074312A1 (en) 2001-03-16 2002-09-26 Pfizer Limited Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors
WO2002074298A1 (fr) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
IL158262A0 (en) 2001-04-16 2004-05-12 Schering Corp 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002092002A2 (en) 2001-05-11 2002-11-21 The Burnham Institute Screening, diagnostic and therapeutic methods relating to riz
WO2002094183A2 (en) 2001-05-18 2002-11-28 Tap Pharmaceutical Products Inc. A method for tumor treatment with fumagillol derivatives
AU2002305669B2 (en) 2001-05-21 2008-09-11 E.I. Du Pont De Nemours And Company Diamide invertebrate pest control agents containing a non-aromatic heterocyclic ring
AU2002312370A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Antipathogenic benzamide compounds
US6916798B2 (en) 2001-08-03 2005-07-12 Vertex Pharmaceuticals Incorporated Inhibitors of GSK-3 and uses thereof
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
CA2457922A1 (en) 2001-08-31 2003-03-13 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
BR0214031A (pt) 2001-11-08 2004-10-19 Upjohn Co Compostos de heteroarila azabicìclico substituìdos para o tratamento de doenças
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
BR122016021801B8 (pt) 2002-01-22 2021-05-25 Warner Lambert Co compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
US7205307B2 (en) 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
EP2082737B1 (en) 2002-03-04 2014-12-31 Merck HDAC Research, LLC Methods of inducing terminal differentiation
ATE486600T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
CN100549011C (zh) 2002-09-19 2009-10-14 先灵公司 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶
WO2004039795A2 (en) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
BRPI0410127A (pt) 2003-05-09 2006-05-09 Pharmacia & Upjohn Co Llc derivados de pirimidina substituìdos
WO2005000356A1 (ja) 2003-06-27 2005-01-06 Ono Pharmaceutical Co., Ltd. 尿路疾患治療剤
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CA2532965C (en) * 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
SE0303396D0 (sv) 2003-12-16 2003-12-16 Astrazeneca Ab Chemical compounds
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
AU2005221834B2 (en) 2004-03-11 2010-09-30 4Sc Ag Sulphonylpyrroles as HDAC inhibitors
US20060084691A1 (en) 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
US20080139620A1 (en) 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
CN101146533A (zh) 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 吡唑激酶抑制剂和其它抗肿瘤剂的组合
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
WO2008007113A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
AR052660A1 (es) 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
US20090156582A1 (en) 2005-02-09 2009-06-18 Tetsuya Tsukamoto Pyrazole Compound
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
EP2027109A1 (en) 2006-05-05 2009-02-25 Astex Therapeutics Limited 4- (2, 6-dichloro-benzoylamino) -1h-pyrazole-s-carboxylic acid (1-methanesulph0nyl-piperidin-4-yl) -amide for the treatment of cancer
EP2026805A1 (en) 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
US20110159111A1 (en) 2006-06-29 2011-06-30 Astex Therapeutics Limited Pharmaceutical combinations
EP2049516A2 (en) 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical compounds
JP2009543770A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
JP2009544602A (ja) 2006-07-21 2009-12-17 アステックス・セラピューティクス・リミテッド サイクリン依存性キナーゼ阻害剤の医学的使用
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations

Also Published As

Publication number Publication date
NO20073957L (no) 2007-10-12
CA2593560A1 (en) 2006-07-27
AU2006207323B2 (en) 2012-06-07
IL184504A0 (en) 2007-10-31
JP2008528470A (ja) 2008-07-31
PE20061018A1 (es) 2006-10-31
CA2593560C (en) 2014-12-09
JP5184892B2 (ja) 2013-04-17
RU2007131100A (ru) 2009-02-27
US20090012124A1 (en) 2009-01-08
SA06260465B1 (ar) 2010-06-20
MX2007008783A (es) 2007-09-11
NO340738B1 (no) 2017-06-06
EP1846393A2 (en) 2007-10-24
MA29256B1 (fr) 2008-02-01
US20110274616A1 (en) 2011-11-10
KR20070107050A (ko) 2007-11-06
US8293767B2 (en) 2012-10-23
KR101344691B1 (ko) 2013-12-26
RU2410385C2 (ru) 2011-01-27
AU2006207323A1 (en) 2006-07-27
EP1846393B1 (en) 2020-02-19
WO2006077426A3 (en) 2006-09-28
PE20091785A1 (es) 2009-12-16
AR054425A1 (es) 2007-06-27
NZ556471A (en) 2010-12-24
IL184504A (en) 2015-10-29
US8013163B2 (en) 2011-09-06
TNSN07277A1 (en) 2008-12-31
WO2006077426A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
BRPI0606594A2 (pt) sal de adição de ácido, método de preparação, solução aquosa, bem como uso do mesmo, processo para preparação de piperidin-4-ilamida do ácido 4-(2,6-dicloro-benzoilamino)-1h-pirazol-3-carboxìlico e uso do mesmo, composição farmacêutica e intermediário quìmico
AR067775A1 (es) (2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de uso
HN2009000502A (es) DERIVADOS DE 2- ARIL-6-FENIL-IMIDAZO[ 1,2-a] PIRIDINAS SU PREPARACION Y SU APLICACION EN TERAPEUTICA
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
BR112013032415A2 (pt) "trans-7-oxo-6-(sulfoóxi)-1,6-diazabiciclo[3,2,1]octano-2-car-boxiamida e ({[(2s,5r)-2-carbamoil-7-oxo-1,6-diazabiciclo[3.2.1]oct-6-5 il]óxi}sulfonil)oxidanida, processos para sua preparação, e intermediários".
BR112015000088A8 (pt) Composições farmacêuticas compreendendo rifamixina e aminoácidos e seus processos de preparação
UA109774C2 (uk) Кристалічні форми саксагліптину та процес його одержання (варіанти)
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
BRPI0821653B8 (pt) composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
AR059296A1 (es) Compuesto de l-tartrato de s-zopiclona y proceso para resolver los enantiomeros de zopiclona.
AR064968A1 (es) Metodo de preparacion de sucralosa por deacilacion de acilato de 6-sucralosa.
BRPI0414436A (pt) processo para a preparação de derivados de 2-oxo-1-pirrolidina e seus sais
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
UY28528A1 (es) Nuevos compuestos
BRPI0614062B8 (pt) processo para preparar brometo de tiotrópio, composto de partida ou intermediário e seus usos
EA201070228A1 (ru) Тразодон и гидрохлорид тразодона в очищенной форме
NO20090748L (no) Fremgangsmate for rensing av montelukast
EA200801960A1 (ru) Соли дулоксетина
ATE532516T1 (de) Verfahren zur synthese von glyt-1-hemmern
DE502006007928D1 (de) Feste salzzubereitung, deren herstellung und verwendung
ATE472523T1 (de) Verbessertes verfahren zur herstellung von rivastigmin
DK2234974T3 (da) Fremgangsmåde til fremstilling af (S)-1-alkyl-2',6'-pipecoloxylidid-forbindelse
DE602006008335D1 (de) Neuartiges verfahren zur herstellung von quaternärer säure und ammoniumsalzen
BR0107804A (pt) Processo para a preparação de acetil-amidiniofenilalanil-ciclohexilglicil-piridinioa laninamidas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL